# ClearPoint Neuro, Inc. (CLPT)

Informational only - not investment advice.

CIK: 0001285550
SIC: 3841 Surgical & Medical Instruments & Apparatus
SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3841 Surgical & Medical Instruments & Apparatus](/industry/3841/)
Latest 10-K filed: 2026-03-17
SEC page: https://www.sec.gov/edgar/browse/?CIK=1285550
Filing source: https://www.sec.gov/Archives/edgar/data/1285550/000119312526111231/clpt-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-17 · accession 0001193125-26-111231 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001285550.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 36,971,000 USD | 2025 | verified |
| Net income | -25,540,000 USD | 2025 | verified |
| Assets | 97,747,000 USD | 2025 | verified |
| Free cash flow | -24,447,000 USD | 2025 | computed |
| Net margin | -69.08% | 2025 | computed |
| Operating margin | -65.36% | 2025 | computed |
| Revenue YoY | +17.78% | 2025 | computed |
| ROE | -91.15% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | CLPT | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -69.1% | -6.0% | 8 | 63 |
| Operating margin | -65.4% | -2.7% | 5 | 63 |
| Revenue growth | 17.8% | 13.6% | 67 | 64 |
| FCF margin | -66.1% | 0.2% | 8 | 63 |
| ROE | -91.1% | -9.1% | 9 | 58 |
| ROA | -26.1% | -4.8% | 19 | 65 |
| Liabilities / equity | 2.49 | 0.89 | 81 | 63 |
| Current ratio | 5.91 | 3.23 | 77 | 65 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 3841 Surgical & Medical Instruments & Apparatus, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 36971000 | USD | 2025 | 2026-03-17 |
| Net income | -25540000 | USD | 2025 | 2026-03-17 |
| Assets | 97747000 | USD | 2025 | 2026-03-17 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-17. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001285550.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 5,749,454 | 7,379,525 | 7,353,266 | 11,217,000 | 12,829,000 | 16,299,000 | 20,551,000 | 23,955,000 | 31,390,000 | 36,971,000 |
| Net income | -8,069,895 | -7,167,353 | -6,163,469 | -5,540,000 | -6,782,000 | -14,410,000 | -16,435,000 | -22,089,000 | -18,914,000 | -25,540,000 |
| Operating income | -7,488,738 | -6,335,837 | -5,247,768 | -4,594,000 | -6,220,000 | -13,374,000 | -16,332,000 | -22,446,000 | -19,734,000 | -24,164,000 |
| Gross profit |  |  |  |  | 9,120,000 | 11,123,000 | 13,531,000 | 13,614,000 | 19,122,000 | 22,692,000 |
| Diluted EPS |  |  |  |  |  | -0.69 | -0.68 | -0.90 | -0.70 | -0.90 |
| Operating cash flow | -5,820,043 | -5,992,511 | -4,630,592 | -2,850,000 | -7,807,000 | -12,697,000 | -16,167,000 | -13,720,000 | -8,950,000 | -23,925,000 |
| Capital expenditures | 101,002 | 26,752 | 63,490 | 10,000 | 41,000 | 168,000 | 253,000 | 717,000 | 275,000 | 522,000 |
| Assets | 7,400,885 | 13,897,365 | 7,856,833 | 11,927,000 | 29,518,000 | 65,581,000 | 55,490,000 | 42,661,000 | 39,189,000 | 97,747,000 |
| Liabilities | 8,156,954 | 8,068,625 | 6,345,831 | 7,341,000 | 27,141,000 | 16,794,000 | 18,603,000 | 21,488,000 | 13,800,000 | 69,727,000 |
| Stockholders' equity | -756,069 | 5,828,740 | 1,510,000 | 4,586,000 | 2,377,000 | 48,787,000 | 36,887,000 | 21,173,000 | 25,389,000 | 28,020,000 |
| Cash and cash equivalents | 3,315,774 | 9,289,831 | 3,101,000 | 5,696,000 | 20,099,000 | 54,109,000 | 27,615,000 | 23,140,000 | 20,104,000 | 45,923,000 |
| Free cash flow | -5,921,045 | -6,019,263 | -4,694,082 | -2,860,000 | -7,848,000 | -12,865,000 | -16,420,000 | -14,437,000 | -9,225,000 | -24,447,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | -140.36% | -97.12% | -83.82% | -49.39% | -52.86% | -88.41% | -79.97% | -92.21% | -60.25% | -69.08% |
| Operating margin | -130.25% | -85.86% | -71.37% | -40.96% | -48.48% | -82.05% | -79.47% | -93.70% | -62.87% | -65.36% |
| Return on equity |  | -122.97% | -408.18% | -120.80% | -285.32% | -29.54% | -44.55% | -104.33% | -74.50% | -91.15% |
| Return on assets | -109.04% | -51.57% | -78.45% | -46.45% | -22.98% | -21.97% | -29.62% | -51.78% | -48.26% | -26.13% |
| Liabilities / equity |  | 1.38 | 4.20 | 1.60 | 11.42 | 0.34 | 0.50 | 1.01 | 0.54 | 2.49 |
| Current ratio | 2.02 | 2.90 | 3.56 | 2.71 | 7.96 | 13.02 | 7.54 | 4.87 | 3.22 | 5.91 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-03. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001285550.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.15 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.23 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.29 | reported discrete quarter |
| 2023-Q3 | 2023-06-30 |  | -7,052,000 |  | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 5,762,000 |  | -0.20 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 6,810,000 | -4,619,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 7,639,000 | -4,146,000 | -0.16 | reported discrete quarter |
| 2024-Q2 | 2024-03-31 |  | -4,146,000 |  | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 7,858,000 |  | -0.16 | reported discrete quarter |
| 2024-Q3 | 2024-06-30 |  | -4,408,000 |  | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 8,122,000 |  | -0.18 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 7,771,000 | -5,386,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 8,485,000 | -6,026,000 | -0.22 | reported discrete quarter |
| 2025-Q2 | 2025-03-31 |  | -6,026,000 |  | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 9,215,000 |  | -0.21 | reported discrete quarter |
| 2025-Q3 | 2025-06-30 |  | -5,837,000 |  | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 8,861,000 |  | -0.21 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 10,410,000 | -7,786,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 12,128,000 | -9,552,000 | -0.32 | reported discrete quarter |
| 2026-Q2 | 2026-03-31 |  | -9,552,000 |  | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 10,880,000 |  | -0.38 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from CLPT's latest 10-K: [/company/CLPT/business/](/company/CLPT/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from CLPT's latest 10-K: [/company/CLPT/risk-factors/](/company/CLPT/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1285550/000119312526330842/clpt-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-03
Report date: 2026-06-30

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and the related notes thereto appearing in Part I, Item 1 of this Quarterly Report. This discussion and analysis contains forward-looking statements that are based upon current expectations and involve risks, assumptions and uncertainties. You should review the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 10-K") and in Part II, Item 1.A of this Quarterly Report for a discussion of important risk factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis. In addition, historical results and trends that might appear in this Quarterly Report should not be interpreted as being indicative of future operations.

Overview

We are a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. We have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling MRI-guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies developed by our company. Over the past several years, we have expanded our capabilities beyond the MRI suite to include operating room based neurosurgical device products and a growing portfolio of services that support pharmaceutical and biotechnology partners developing gene and cell therapies. In 2025, with the acquisition of IRRAS, we expanded our portfolio into neurocritical care, focusing on treatments for intracerebral hemorrhage, intraventricular hemorrhage, and other conditions requiring intracranial fluid management.

Our business today consists of two integrated components: (i) a business providing medical devices for neurosurgical applications, and (ii) a business focused on partnerships in the biologics and drug delivery space.

Our primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide: (a) the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters; and (b) the infusion of pharmaceuticals into the brain. The ClearPoint system was originally designed for use in an MRI setting. In 2021, we launched the SmartFrame Array Neuro Navigation System and Software, which allows for operating room placement of the ClearPoint system and completion of the procedure in the MRI suite. In 2024, we introduced the SmartFrame OR Stereotactic System to the market, which allows for complete procedures to be performed in the operating room. In 2025, we released the ClearPoint Navigation Software Version 3.0, which allows for the ClearPoint system navigation software to support end-to-end procedures in the operating room.

In 2022, we commenced commercialization of the ClearPoint Prism Neuro Laser Therapy System, a laser ablation system. The ClearPoint Prism Neuro Laser Therapy System was developed and is manufactured for us by CLS. We have exclusive global rights to commercialize the system for neuro applications.

In 2025, through the acquisition of IRRAS, we added the IRRAflow system to our portfolio of medical devices. The IRRAflow system integrates continuous irrigation, drainage, and real-time intracranial pressure monitoring to provide controlled, automated intracranial fluid management within neurocritical care and operating room settings.

The second component of our business is focused on partnerships in the biologics and drug delivery space, supporting our customers from the earliest stages of their research through their clinical study and commercialization process. Since 2021, a growing and significant part of the revenue from our business has been derived from preclinical development services, which include protocol consultation and solutions for preclinical study design and execution. Our consulting services include a core competency of in vivo biology services in large and small research models to assist our customers with establishing drug safety prior to and in support of their human clinical trials.

23

Currently, we have more than 60 biologics and drug delivery customers who are evaluating using our products and services in trials to inject gene and cell therapies directly into the brain. These customers have drug development programs at various stages of development, ranging from preclinical research to late-stage regulatory trials for multiple distinct disease states. This part of our business potentially represents the largest opportunity for growth; however, our ability to grow in this market is dependent on our ability to maintain and establish new relationships with pharmaceutical company customers, such customers' continuation of research and product development plans, such customers successfully completing clinical trials and obtaining regulatory approvals of their drugs and biologics, and such customers’ realization of commercial success for their therapies, including overcoming barriers in reimbursement, physician adoption, and patient access to their therapies. In 2024, the U.S. Food and Drug Administration (the “FDA”) granted marketing authorization for our SmartFlow cannula to be used to deliver a gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency to regions of interest within the brain.

Factors Which May Influence Future Results of Operations

The following is a description of factors that may influence our future results of operations, and that we believe are important to an understanding of our business and results of operations.

Macroeconomic Trends

We continue to monitor the impacts of various macroeconomic trends, such as inflationary pressure, changes in monetary policy, constraints on hospital capital spending, the introduction of or changes in tariffs or trade barriers, and global or local recession and geopolitical instability. Such changes in domestic and global macroeconomic conditions may lead to increased costs for our business. Additionally, these macroeconomic trends could adversely affect our customers, which could impact their willingness to spend on our products and services, or their ability to make payments, which could harm our collection of accounts receivable and financial results. In particular, a portion of our revenue is derived from products and services supporting pharmaceutical and biotechnology partners' preclinical and clinical development programs, and constraints in the funding environment for these partners, whether due to capital markets conditions or changes in government research funding, could cause partners to delay, scale back or discontinue programs utilizing our products and services. The world’s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result, our ability to access capital markets and other funding sources may not be available in the future on commercially reasonable terms, if at all. We cannot predict with certainty the ultimate impact of these trends on our business, financial condition, results of operations or cash flows, which will depend on future developments. To date, these trends have not had a material adverse impact on our business, financial condition or results of operations.

Revenue

In 2010, we received 510(k) clearance from the FDA to market our ClearPoint system in the U.S. for general neurosurgical procedures; in February 2011 and May 2018, we also obtained CE marking for our ClearPoint system and SmartFlow Neuro cannula, respectively; and in June 2020 we obtained CE marking for version 2.0 of our ClearPoint software and our Inflexion head fixation frame. In January 2021, we received 510(k) clearance for the SmartFrame Array Neuro Navigation System. In September 2022, the ClearPoint Prism Neuro Laser Therapy System, for which we have exclusive global rights to commercialize, received 510(k) clearance through our Swedish partner, CLS. The Prism laser is the first therapy product we have commercialized. In January 2024, we received 510(k) clearance from the FDA for the SmartFrame OR Stereotactic System.

In 2021, we started providing consulting services to our pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. Our expertise is concentrated in

24

benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and over-arching translation from the preclinical to the clinical setting to enhance accuracy and precision of drug delivery.

Our neurosurgery navigation and therapy revenue primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint and IRRAflow systems. Generating recurring revenue from the sale of disposable products is an important part of our business model. Future revenue from sales of such products is difficult to predict and may not be sufficient to offset our continuing research and development expenses and our increasing selling, general and administrative expenses. As a result of the IRRAS acquisition, revenue is expected to grow over the coming years due to a larger combined organization, expanded product offerings, and increased customer reach, both in the U.S. and internationally.

Our biologics and drug delivery revenue comes from sales of products, including disposable products, and services related to customer-sponsored preclinical and clinical trials utilizing our products. Our biologics and drug delivery customers are pharmaceutical and biotech companies, academic institutions, and customer-sponsored contract research organizations that are developing methods to deliver a wide variety of molecules, genes or proteins to targeted brain tissue or structures (our “Partners”) that would need to bypass the blood-brain barrier for the treatment of a variety of disorders. This is a novel area in which commercialization must be preceded by FDA-mandated clinical trials, which are expensive and time consuming to conduct, and for which the commercial success is uncertain, pending, in part, on the outcome of those trials. The number of Partner relationships is of importance as we recognize the possibility that some Partners’ research will reach commercial success, and others may not. To the extent our Partners achieve commercial success, our expectation is that we will share in such success through our Partners’ use of our products and services in their delivery of therapies. At June 30, 2026, we had more than 60 Partners, similar to the number of Partners as of the same date in 2025.

Our capital equipment and software revenue consists of sales of ClearPoint and IRRAflow reusable hardware and software and related services.

Substantially all our revenue for the three and six months ended June 30, 2026 and 2025 relates to: (i) sales of our ClearPoint and IRRAflow system products and related services; and (ii) consulting services provided to our biologics and drug delivery customers. Our product revenue was $7.4 million and $16.2 million for the three and six months ended June 30, 2026, respectively, and was almost entirely related to our ClearPoint system. Our service revenue was $3.5 million and $6.8 million for the three and six months ended June 30, 2026, respectively

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1285550/000119312526111231/clpt-20251231.htm
Complete FY 2025 MD&A: /company/CLPT/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-17
Report date: 2025-12-31

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes thereto included elsewhere in this Annual Report. This discussion and analysis contains forward-looking statements that are based upon current expectations and involve risks, assumptions and uncertainties. You should review the “Risk Factors” section of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis.

Overview

We are a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. We have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling MRI-guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies developed by our company. Over the past several years, we have expanded our capabilities beyond the MRI suite to include operating room based neurosurgical device products and a growing portfolio of services that support pharmaceutical and biotechnology partners developing gene and cell therapies. In 2025, with the acquisition of IRRAS, we expanded our portfolio into neurocritical care, focusing on treatments for intracerebral hemorrhage, intraventricular hemorrhage, and other conditions requiring intracranial fluid management.

Our business today consists of two integrated components: (i) a business providing medical devices for neurosurgical applications, and (ii) a business focused on partnerships in the biologics and drug delivery space.

Our primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide: (a) the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters; and (b) the infusion of pharmaceuticals into the brain. The ClearPoint system was originally designed for use in an MRI setting. In 2021, we launched the SmartFrame Array Neuro Navigation System and Software, which allows for operating room placement of the ClearPoint system and completion of the procedure in the MRI suite. In 2024, we introduced the SmartFrame OR Stereotactic System to the market, which allows for complete procedures to be performed in the operating room. In 2025, we released the ClearPoint Navigation Software Version 3.0, which allows for the ClearPoint system navigation software to support end-to-end procedures in the operating room.

In 2022, we commenced commercialization of the ClearPoint Prism Neuro Laser Therapy System, a laser ablation system. The ClearPoint Prism Neuro Laser Therapy System was developed and is manufactured for us by CLS. We have exclusive global rights to commercialize the system for neuro applications.

In 2025, through the acquisition of IRRAS, we added the IRRAflow system to our portfolio of medical devices. The IRRAflow system integrates continuous irrigation, drainage, and real-time intracranial pressure monitoring to provide controlled, automated intracranial fluid management within neurocritical care and operating room settings.

The second component of our business is focused on partnerships in the biologics drug and delivery space, supporting our customers from the earliest stages of their research through their clinical study and commercialization process. Since 2021, a growing and significant part of the revenue from our business has been derived from preclinical development services, which include protocol consultation and solutions for preclinical study design and execution. Our consulting services include a core competency of in vivo biology services in large and small research models to assist our customers with establishing drug safety prior to and in support of their human clinical trials.

Currently, we have more than 60 biologics and drug delivery customers who are evaluating using our products and services in trials to inject gene and cell therapies directly into the brain. These partnerships involve drug development programs that are at various stages of development ranging from preclinical research to late-stage regulatory trials for multiple distinct disease states. This part of our business potentially represents the largest opportunity for growth; however, our ability to grow in this market is dependent on our ability to maintain and establish new relationships with pharmaceutical company customers, such customers' continuation of research and product development plans, such customers achieving success in completion of clinical trials and subsequent regulatory approvals of their drugs and biologics, and such customers’ realization of commercial success for their therapies, including overcoming barriers in reimbursement, physician adoption, and patient access to their therapies. In 2024, the U.S. Food and Drug Administration (the “FDA”) granted marketing authorization for our SmartFlow cannula to be used to deliver a gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency to regions of interest within the brain.

49

Table of Contents

2025 Milestones and Developments

•
Completed the acquisition of IRRAS, which brings the IRRAflow active fluid-exchange system into our product portfolio, a differentiated technology designed to modernize the management of intracranial bleeding.

•
Entered into a debt financing arrangement with an affiliate of Oberland Capital Management under which we may borrow up to $105.0 million from time to time in tranches; we raised approximately $48.1 million in net proceeds under this arrangement during 2025.

•
Raised approximately $3.3 million in net proceeds from the sale of shares of our common stock to an affiliate of Oberland Capital Management.

•
Entered into a lease for the new preclinical research facility named ClearPoint Advanced Laboratories (CAL) located in San Diego, California, allowing for additional capacity to perform larger studies, and the ability to offer additional services to biopharma partners.

•
Several of our partners advanced through preclinical and clinical review, with over ten pharmaceutical partners receiving expedited US FDA review designations.

•
Received the following regulatory approvals:

o
FDA Clearance for the ClearPoint 3.0 Software which includes both operating room navigation capability and features enhanced for laser therapy applications;

o
FDA 510(k) clearance expanding compatibility of the ClearPoint PRISM Neuro Laser Therapy System with 1.5T scanners in addition to the previously cleared 3T compatible system;

o
European Medical Device Regulation (EU MDR) certification for the SmartFlow Neuro Cannula; and

o
Several expanded regulatory approvals for product use in Canada, Hong Kong, and Taiwan, bringing the total number of international clearances for key therapy delivery products to 34 countries worldwide.

Factors Which May Influence Future Results of Operations

The following is a description of factors which may influence our future results of operations, and that we believe are important to an understanding of our business and results of operations.

Macroeconomic Trends

We continue to monitor the impacts of various macroeconomic trends, such as inflationary pressure, changes in monetary policy, decreasing consumer confidence and spending, the introduction of or changes in tariffs or trade barriers, and global or local recession. Such changes in domestic and global macroeconomic conditions may lead to increased costs for our business. Additionally, these macroeconomic trends could adversely affect our customers, which could impact their willingness to spend on our products and services, or their ability to make payments, which could harm our collection of accounts receivable and financial results. The world’s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result, our ability to access capital markets and other funding sources in the future may not be available on commercially reasonable terms, if at all. The rapid development and fluidity of these situations precludes any prediction as to the ultimate impact they will have on our business, financial condition, results of operation and cash flows, which will depend largely on future developments.

Revenues

In 2010, we received 510(k) clearance from the FDA to market our ClearPoint system in the U.S. for general neurosurgical procedures; in February 2011 and May 2018, we also obtained CE marking for our ClearPoint system and SmartFlow Neuro cannula, respectively; and in June 2020 we obtained CE marking for version 2.0 of our ClearPoint software and our Inflexion head fixation frame. In January 2021, we received 510(k) clearance for the SmartFrame Array Neuro Navigation System. In September 2022, the ClearPoint Prism Neuro Laser Therapy System, for which we have exclusive global rights to commercialize, received 510(k) clearance through our Swedish partner, CLS. The Prism laser is the first therapy product we have commercialized. In January 2024, we received 510(k) clearance from the FDA for the SmartFrame OR Stereotactic System.

In 2021, we started providing consulting services to our pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. Our expertise is concentrated in benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and over-arching translation from the preclinical to the clinical setting to enhance accuracy and precision of drug delivery.

Future revenue from sales of our ClearPoint platform products and services is difficult to predict and may not be sufficient to offset our continuing research and development expenses and our increasing selling, general and administrative expenses. As a result of the IRRAS acquisition, revenue is expected to grow over the coming years due to a larger combined organization, expanded product offerings, and increased customer reach, both in the U.S. and internationally.

50

Table of Contents

Generating recurring revenue from the sale of products remains an important part of our business model for our ClearPoint system. Our product revenue was approximately $23.9 million and $18.6 million for the years ended December 31, 2025 and 2024, respectively, and was almost entirely related to our ClearPoint system. Our service revenue was approximately $13.1 million and $12.8 million for the years ended December 31, 2025 and 2024, respectively, of which 89% and 92%, respectively, related to the biologics and drug delivery service line.

Our revenue recognition policies are more fully described in Note 2 to the consolidated financial statements elsewhere in this Annual Report.

Underlying the revenue from sales of products and services to our biologics and drug delivery customers is the number of direct customers and end users of our products and/or services (“Partners”). Our Partners consist of pharmaceutical and biotech companies, academic institutions, or customer-sponsored contract research organizations that are developing methods to deliver a wide variety of molecules, genes or proteins to targeted brain tissue or structures that would need to bypass the blood-brain barrier for the treatment of a variety of disorders. This is a no

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/CLPT/mda/fy2025/
All MD&A years: /company/CLPT/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/CLPT/mda/fy2024/): filed 2025-02-26; accession 0000950170-25-027934 (https://www.sec.gov/Archives/edgar/data/1285550/000095017025027934/clpt-20241231.htm)
- [FY 2023 MD&A](/company/CLPT/mda/fy2023/): filed 2024-03-12; accession 0001285550-24-000031 (https://www.sec.gov/Archives/edgar/data/1285550/000128555024000031/clpt-20231231.htm)
- [FY 2022 MD&A](/company/CLPT/mda/fy2022/): filed 2023-03-01; accession 0001285550-23-000020 (https://www.sec.gov/Archives/edgar/data/1285550/000128555023000020/clpt-20221231.htm)
- [FY 2021 MD&A](/company/CLPT/mda/fy2021/): filed 2022-03-09; accession 0001285550-22-000003 (https://www.sec.gov/Archives/edgar/data/1285550/000128555022000003/clpt-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 3841 Surgical & Medical Instruments & Apparatus) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/CLPT.md · JSON record: /company/CLPT.json · verified financials: /company/CLPT/financials.json / /company/CLPT/financials.csv · machine TOC for the whole site: /llms.txt